0001193125-14-005423.txt : 20140108 0001193125-14-005423.hdr.sgml : 20140108 20140108162133 ACCESSION NUMBER: 0001193125-14-005423 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 4 CONFORMED PERIOD OF REPORT: 20140107 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20140108 DATE AS OF CHANGE: 20140108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ARCA biopharma, Inc. CENTRAL INDEX KEY: 0000907654 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 363855489 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-22873 FILM NUMBER: 14516664 BUSINESS ADDRESS: STREET 1: 11080 CIRCLEPOINT ROAD STREET 2: SUITE 140 CITY: WESTMINSTER STATE: CO ZIP: 80020 BUSINESS PHONE: 720-940-2200 MAIL ADDRESS: STREET 1: 11080 CIRCLEPOINT ROAD STREET 2: SUITE 140 CITY: WESTMINSTER STATE: CO ZIP: 80020 FORMER COMPANY: FORMER CONFORMED NAME: NUVELO INC DATE OF NAME CHANGE: 20030203 FORMER COMPANY: FORMER CONFORMED NAME: HYSEQ INC DATE OF NAME CHANGE: 19970610 8-K 1 d656131d8k.htm 8-K 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 8, 2014 (January 7, 2014)

 

 

ARCA biopharma, Inc.

(Exact Name of Registrant as Specified in Charter)

 

 

 

Delaware   000-22873   36-3855489

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

11080 CirclePoint Road, Suite 140, Westminster, CO 80020

(Address of Principal Executive Offices) (Zip Code)

(720) 940-2200

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Section 8 — Other Events

Item 8.01. Other Events.

On January 7, 2014, ARCA biopharma, Inc. (“ARCA”) announced that Dr. Michael R. Bristow, president and chief executive officer, will present at the Biotech Showcase 2014, taking place January 13-15, 2014 in San Francisco, California. ARCA’s corporate presentation is scheduled for Tuesday, January 14, 2014 at 3:00 p.m. Pacific Time. The press release is furnished as Exhibit 99.1 hereto, the contents of which are incorporated herein by reference.

Additionally, on January 8, 2014, ARCA announced that the U.S. Food and Drug Administration has accepted the Investigational Device Exemption (“IDE”) application that Laboratory Corporation of America submitted for the planned companion diagnostic test for Gencaro™, a pharmacologically unique beta-blocker and mild vasodilator being developed for atrial fibrillation. The IDE allows the companion diagnostic test to be used in ARCA’s planned GENETIC-AF clinical trial. The press release is furnished as Exhibit 99.2 hereto, the contents of which are incorporated herein by reference.

Section 9 — Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit
Number

   

Description

99.1    Press Release titled “ARCA biopharma to Present at Biotech Showcase 2014” dated January 7, 2014.
99.2    Press Release titled “ARCA biopharma Announces U.S. FDA Acceptance of Gencaro Companion Diagnostic Test IDE” dated January 8, 2014.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: January 8, 2014

 

ARCA biopharma, Inc.

(Registrant)

By:  

/s/Christopher D. Ozeroff

Name:   Christopher D. Ozeroff
Title:   SVP and General Counsel

INDEX TO EXHIBITS

 

Exhibit
Number

   

Description

99.1    Press Release titled “ARCA biopharma to Present at Biotech Showcase 2014” dated January 7, 2014.
99.2    Press Release titled “ARCA biopharma Announces U.S. FDA Acceptance of Gencaro Companion Diagnostic Test IDE” dated January 8, 2014.
 EX-99.1 2 d656131dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

ARCA BIOPHARMA TO PRESENT AT BIOTECH SHOWCASE 2014

Westminster, CO, January 7, 2014 – ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that Dr. Michael R. Bristow, president and chief executive officer, will present at the Biotech Showcase 2014, taking place January 13-15, 2014 in San Francisco, California.

ARCA’s corporate presentation is scheduled for Tuesday, January 14, 2014 at 3:00 p.m. Pacific Time. The Company’s presentation will be posted in the Investor Relations section of its website (www.arcabiopharma.com) and will also be available via public webcast at: http://www.media-server.com/m/p/3qtnqneu.

About ARCA biopharma

ARCA biopharma is dedicated to developing genetically-targeted therapies for cardiovascular diseases. The Company’s lead product candidate, GencaroTM (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for atrial fibrillation. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically-targeted atrial fibrillation prevention treatment. ARCA has a collaboration with Medtronic, Inc. for support of the GENETIC-AF trial. For more information please visit www.arcabiopharma.com.

Safe Harbor Statement

This press release and the anticipated presentation contain “forward-looking statements” for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding, potential timing for patient enrollment in the GENETIC-AF trial, the sufficiency of the Company’s capital to support its operations, the potential for genetic variations to predict individual patient response to Gencaro, Gencaro’s potential to treat atrial fibrillation, future treatment options for patients with atrial fibrillation, the role of AF burden in diagnosis and treatment of atrial fibrillation and the potential for Gencaro to be the first genetically-targeted atrial fibrillation prevention treatment. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the risks and uncertainties associated with: the Company’s financial resources and whether they will be sufficient to meet the Company’s business objectives and operational requirements; results of earlier clinical trials may not be confirmed in future trials, the protection and market exclusivity provided by the Company’s intellectual property; risks related to the drug discovery and the

regulatory approval process; and, the impact of competitive products and technological changes. These and other factors are identified and described in more detail in ARCA’s filings with the SEC, including without limitation the Company’s annual report on Form 10-K for the year ended December 31, 2012, and subsequent filings. The Company disclaims any intent or obligation to update these forward-looking statements.

Investor & Media Contact:

Derek Cole

720.940.2163

derek.cole@arcabiopharma.com

###

EX-99.2 3 d656131dex992.htm EX-99.2 EX-99.2

Exhibit 99.2

 

LOGO

ARCA BIOPHARMA ANNOUNCES US FDA ACCEPTANCE OF GENCARO COMPANION DIAGNOSTIC TEST IDE

 

 

Phase 2B/3 GENETIC-AF Trial on Track to Begin Patient Enrollment in Q1 2014

 

 

Gencaro Potentially the First Genetically-Targeted Cardiovascular Treatment

Westminster, CO, January 8, 2014 – ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that Laboratory Corporation of America (LabCorp®) (NYSE: LH) has informed ARCA that the U.S. Food and Drug Administration (FDA) has accepted LabCorp’s Investigational Device Exemption (IDE) application for the planned companion diagnostic test for GencaroTM (bucindolol hydrochloride), a pharmacologically unique beta-blocker and mild vasodilator being developed for atrial fibrillation (AF). The IDE allows the companion diagnostic test to be used in the planned GENETIC-AF clinical trial. ARCA’s Gencaro Investigational New Drug (IND) application for AF has been accepted by the U.S. Food and Drug Administration (FDA) and is active.

ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically-targeted AF prevention treatment. LabCorp and ARCA have developed the companion diagnostic test for Gencaro to identify patient genotypes based on these genetic variations of the beta-1 cardiac receptor. LabCorp will provide the patient genetic testing for ARCA’s GENETIC-AF clinical trial of Gencaro, which is expected to begin patient enrollment in the first quarter of 2014.

GENETIC-AF Clinical Trial

GENETIC-AF is planned as a Phase 2B/3, multi-center, randomized, double-blind clinical trial comparing Gencaro to Toprol-XL for prevention of AF in patients with heart failure and reduced left ventricular ejection fraction (HFREF). ARCA plans to enroll only patients with the genetic variant of the beta-1 cardiac receptor which the Company believes responds most favorably to Gencaro. GENETIC-AF has an adaptive design, under which the Company plans to initiate it as a Phase 2B study in approximately 200 patients and then, depending on the results of an interim analysis by the trial Data Safety Monitoring Board (DSMB), expand the trial to a Phase 3 study by enrolling an estimated additional 420 patients. Medtronic, Inc. is collaborating with ARCA on the GENETIC-AF trial. The Company anticipates that patient enrollment in GENETIC-AF will begin in the first quarter of 2014.

About ARCA biopharma

ARCA biopharma is dedicated to developing genetically-targeted therapies for cardiovascular diseases. The Company’s lead product candidate, GencaroTM (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for atrial fibrillation. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically-targeted atrial fibrillation prevention treatment. ARCA has a collaboration with Medtronic, Inc. for support of the GENETIC-AF trial. For more information please visit www.arcabiopharma.com.

Safe Harbor Statement

This press release contains “forward-looking statements” for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding, potential timing for patient enrollment in the GENETIC-AF trial, the sufficiency of the Company’s capital to support its operations, the potential for genetic variations to predict individual patient response to Gencaro, Gencaro’s potential to treat atrial fibrillation, future treatment options for patients with atrial fibrillation, the role of AF burden in diagnosis and treatment of atrial fibrillation and the potential for Gencaro to be the first genetically-targeted atrial fibrillation prevention treatment. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the risks and uncertainties associated with: the Company’s financial resources and whether they will be sufficient to meet the Company’s business objectives and operational requirements; results of earlier clinical trials may not be confirmed in future trials, the protection and market exclusivity provided by the Company’s intellectual property; risks related to the drug discovery and the regulatory approval process; and, the impact of competitive products and technological changes. These and other factors are identified and described in more detail in ARCA’s filings with the SEC, including without limitation the Company’s annual report on Form 10-K for the year ended December 31, 2012, and subsequent filings. The Company disclaims any intent or obligation to update these forward-looking statements.

Investor & Media Contact:

Derek Cole

720.940.2163

derek.cole@arcabiopharma.com

###

GRAPHIC 4 g656131img1.jpg GRAPHIC begin 644 g656131img1.jpg M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$" M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,# M`P,#`P,#`P,#_\``$0@`2@#4`P$1``(1`0,1`?_$`+X````&`P$!```````` M```````&!P@)"@$"!0,$`0$``@("`P$``````````````0,'"`0&`@D*!1`` M`00!`P(#!`4&"0H'`````@$#!`4&`!$'$@@A,1,B%!4)05$RE!9A<8%2(Q>1 ML4)RPC-#@S>A)#0E1;4V=A@*P6*"LE-4.!$``@$#`@0#!08""`<```````$" M$0,$!08A,1('05$388$B0@CP<9&Q,A318J'A4G*",R0)DB.S9!46)O_:``P# M`0`"$0,1`#\`N)]SO=>7$W-TUS\Q^EAV_E_MKS(^![D^XR]FD\O)V0Q/5<15;KVJJ)'9%2^R,=JO0 M!1-_#S5=O/7K,ROJK^I+<&K?Z/Y6R_KZ]:7J/X76SR?)_Y/D?F7M'V(H2G#3L:D&T^$O# M_$:2^4NY4);D-KE3+_51]UA$1VO]GTC)#(E*O\@$55?R)OKQS>[GU6VLF6%; MW7K7JX]Z76ZVN,4VN/\`R?8>,-'V-."FM.QN*3Y2\?\`$$Y>Y3N,HI@R?WGY M%+%LE0`GQZJ5&/9=]WHSL#I,"1/SZZOC?55]2VBZT\N>X=2R[-N;7H7G:Z)4 M?LM)T]Y^Q#8^S=4Q'Z.#CVITYKJ3_'J)".V+NQ7ER2N&9HS$J\Y9BG*@2(6[ M5=DL9D4603,R_Z6?J\Q.\N7+9.\[<=/[B6+?7 M&*=+.1"BITOD[GC**\^'(PMOOMS>VK..7B2=W3IT;?/HK\K?LY?F/81P]DV- M53Z_#Q_@UO0G)I.2I*G%>3\O<8O=*\.0/4/]9=20#U#_`%ET`T>%WI\03^\2 MV[)&)\X^6ZCC1GDB5)%8BT/2XXV^YB;;R2%F?B>/0R&[(VU:Z!BFB[[[IH!W M'J'^L7Z?!?TI]"Z`'J'^LN@(^^X'YE_;YVOY=>8IS+0<\XW%HG8S+N=L\'YM M;<;3EE1H\H'*K-H$-ZHL&@21Z9D);"Z)!]I-M`(*U\]3Y>4MZ-$JN1.0KVRF MN@Q#J*7B+.;&UFR'%V;BQ(3-9ZS\EU?LB"*2Z`,]G\Y+M'QYAFPS6B[EN.Z% MYUMM,HSGMRY)H<<#U/L$]9O5AML@2;JG4GDF^V@'T<&=R_!7>'J:8O*24,:YIGW$WZ1DL-=>R].^RZ`6_U#_670'A)F MLPHTB9,E,Q(<1AV3+ERGFX\6+&8!7'Y$F0\0,L,,MBI&9J@B*;JN@(R^1OFZ M]G^(YHO&7'E]G7X7G;#>VKA?D/G/D M-^4&)<M+:QD-1V`(D0G'$W79-`=3A'F' M%N?.(N.^9\%D/.XGR1BU7E-,,E6O?(C%BRANUU@C+CK8659)1R/($2(1>:)$ M70"I>H?ZRZ`WZR]/?J7?KVW_`"=.^V@*^_+86&2\U\GRI7JR#_'5]&,T0S$6 M84]V%%;ZEW0`;C101$\/+7S<]ZLC6-=[W[BQ[7J7[L==SH+J;DU&.1<2BFZM M125$EP2X&XNW9XN#M7$E&,8MXMM\/%N";?O?$6OC3C6+D;;41L66KOH'W-MX M@;BW'2.Z11<+I2/9"G]6I*@.KL/@7BN=>U':C$W!;A"-J,=:C&*4;BHG)+PY M<*G3MAS'/60?L MQB4#^CV!76Z6@=I+]_3M.UBU:QK>9BYJL94+WPSC"W+IE.VFU6#HW%^1CO)U M^XYY$,>KLSMN2BN57Q_%&;_B?W"-E=JW#29*N;:52X^S%%'S./.?=D3)C:-; MBBE%3T6RW1=C)?JUS-:[2:?IBU77;48Y>KZCDWK&+9BNJW"VYR5N[*G)N-&W M6A7@[@N7?0L79.W%6X]7AX+^MC2^2N-8N/`]#>1F1>(&TQIGI.-3H8_Z,1]. MSUCTDG7MN+*+M[1;[:1]V^T>G;;P_3OUR=Q1C2:BJ]%Q?JC&G@I52,F:%N"6 M1)1C-QQH\&_"27"OO$1XH&?C/-'&LJ,KK!)FE(P)JA-H;">")X(GU(GEKZ/%+K2GY\?Q-.HJD4O8#4GD)[RSR;BW"_ M&&?\MYO-"!B?&^)7N97TDW!;7W"AKWYYQV5/9"E37&A99#^6ZX(_3H"AME') MO<)VS][W`_?;R_%?@Y#SQ.I^Z*-&;61N[QAG-W9T]EB$@#1%;=@86V,=(Z)T MMLFQX;:DM48T+^F/WU3E5#29103&K"AR.HK;VEL&"0V)M7;PV;"!):)%5%!Z M+($D_/J"HZ^@$[Y=I:K(N*.2Z"\KX=M2VN`YA"LJNPCMRX,R*]06".,/Q7Q- MAT"5=]E'P5$5/+0%)[Y`M/5S_F&4YSH$6:Y1\2\G6%0ZM/,-F.Q;ZDNZ50ORN*(*2DJ"`] M1$9*@@`"BDI&2["(B*>*KJ"DIR=_7>_S3\R7NKINPWM2OYE1PW89PN!OV%5) MDQ6N3K.JD.KE6:93.B$W)+C?&6(4AZ/$0O2E,QE?<0B-L1DM44E5EE[LW[*> M$NR3C"KX]XFQR"-L4*-^-.0I<..N7YY=B`++L[>R0%>9@*^B^ZP6B&-%:1!$ M=]R*"H=Y]*+NNZ>2[KNGZ?/0$,_S8?E]4W/F#PNXOAG!^KNFX8O<9S.D+LK[M^=&63,O1PW`6'6L/QMY&4+:QN[`Y$IE@]O45EI=O)=`<7_MU M>YA,UX.Y&[9KV=ZEYQ#=CFF&QWC57G''#M5_X(C]>-<7E MR8\U=1O0Q,K M=.BVD[-R3618N)7)V8V>J#DD_'A+E6IA_7\V5RZ\?3[LWQHXS_16M*+ARKR" M+CV>R.2LDEVMM*>^&A-?C55A"@1WG&&.MM"Z'I3K8=3KJIU&9?4B:Z!M MW?.H;\W9>S]=NTT.TY8]EN?Q]$&XQZ^FB.;58U%BRZR88H2"$J.V>PFR\J-F0!X(#X">XDGBBIK:+'R-+V MSAXZT[*IC9,8VZ53K*B5>-77[CH[A=NVY2N6ZS3_``H)#R=B$VM&4F/8;'%I M5<-;VRD1K6QDJ:[D_'&7(5J,I[]6Z-J>ZKNNL/=T=IYEB.1*>2;:]<>B:1JF']0>T[[G&XY:QCS^-KJZO7N*LJ?-3 M@ZVB[@5S\:'%7:-Q3E#5?C^9GV]VI\:V:.O>I*?Q4VUM M,%L'=RZE#X0Z<)%V\?K9%Z=M_+4 MES_26K.4OF]]AG'=`]8X_P`X47,&6/H,?%^/.)`F9?D^67DI1:JJ2`L.,M;$ M=L9KC;7J/O`(=6^RKL*P4OF12=CGRNN64@D!B!44D)^QL93I*J(@LQ(Y+^7;0$1ORJ,9M.<87,E*/2[K5?A4HO MV))F)MT863%2=>F*KX"F:89-M7W$8I9++EA0S99K M)D5+L=QQDIS##KJHRXQU[AX$FZ:QWN;L1W)V%O'-S>W6%+JDC]+3-Q[?S]-A@:RY6Q<4K-K4)=>1>ROFLMIKI@I55'QHO,Z[J^=H=BS+'T^=R[ M>;_4O&OS>\YG+-]CTJ78LV<*QQB]CF8R4;<6SJWG/%>OT7B9DL`ZFQ(376)( MN^WBFN#WAW!H-S-RK&NSR-%W%",E;BYREB76JKJHG^B5*KV4.1MO%OPE&Y;E MUQ:K1KC]D,AI9`N)"B-'(ERGW"41:9CQVB(B541$ M30%<+M)X(8^9SW$]U'?AF?(G-/&^'-YRO!_;C:<0YW-X\O'./L,C)'NW7;>! M%>E/55IUQ7#:;4`.6\^I[JFV@'[YI\I_C7.,3R+#[WN?[V[ZIR.HG54VHR?N M-R.^Q^<,I@@9;N*6=".):P`DJ!N,.(HN(.RZ`KN_)VY4R#LT^8YEG;7R+(.I M@\B7&2\&91&DJK,5C/L4M)C^$V2BXH@!SY3#D9LO#J">.R^.I+>E4+N/BG@O MFGG^?4%3YA/Y#_P_SO\`Y+RK_<,_0%(KY"%+37_?_P##KZHJ[NO+SABF&0&ZFO@J])`:/E&IKZP(\>L=C3C%FT)D6Q13:D?:%PE@I?,D>^3=\ MPL.\+A/]V_(]T#_<'PS60:[)BDO-^^Y]AX($.ESYH?961-'I2)9JGE)$75\' MDV`?QWM<1S^>>T?N'XAJ&U=O,XXKRBOH&.G6T#TNQ@-76.V<2XJW)U1.?K+2&W.@NO1CD5]C%<8>$256W0(5V5-M`1$_.5 MY:R)[BCBSLPXOE$O+7>OR+3<9QX\8R697\;L64%S-;5X&E]5J',1YF(1+L), M&_X["NP"GXC\J#C'",6Q_$,=[GN]Z@I,#\OB!V\T?%7\R;.SL/5-HXCM2 MZK]J$(27BNE)-?T!KPCE)RHAE#A/%'>EM^E/G(XH27&"Z4*%')%ZF(J[^VJ+ MU.?3X>?9>VW>1Z#IRQ<>Y.WEWWZ M',=)39].^N5K_>+3=1_\UI&1DRNV M;^9=OXBE+J5J4;DG.5NO)R\:I1@NEU"X]#W\6T55)G=>E=E5-:<=Q>]"US#N6I7 M)7Z9##O9 MKJ;DW&KJ9T9\N4X:(@``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`N2JWD_F MW`:7+H6(9##:X^9R"!89[-M;"CDMU=4QBC`\<2O?? M@JR01L0S#`.9..\@@3L9R;\,7M1E=%+ MA7$!QB=3V9UTF2TRY)@2556G%$^DD)$\EU!24?.XWC#E[Y-O?W2Y?QG+ECBL M6U=S'B:UF..-UN=<86W<#%LWJ\@F*#14;$&U>BLWQ+-7TV' MX)OM2$Z538BZ4@J(:?F>_*=Y?PWF9SO>[%JZP?OF,GC\BYAQOBG2UE6+YQ`F M!9R,\X\@IZ8W$&RF-J]/K`_;`\1DTVZVX8`)ZF2%=C'SAN"NX:DK,`Y\O*SM M\[E:9IFIRO#>02+$*');>*`,2;?$K*\2)'BI-?%2?F..Q*Q&43J]7WY^R"-Z:CX[]6V@(`_FCD;<;W M7U(\0B]57",1'4EJBO%$BW;3F?!?8AV,]MF+BOZLP8D2&VR1AV.T;B="D0R6=*+ MA?\`U6]L?[N?WK_]07#W[M/B?PK\E[71MXZ@J,\Y=ON$\X5T=F^1^LOZX7QJ,FKQ#XA#`R5PHLEIS9JPKW#3= M6CVZ5\145W76O7?#Z=-C]]M,C+<1&6(Y2PW+JE;^5OV^-1B,CY?W)$*8ITV>XC)C":JP[+C6T-[HW%0]5AI MF6"$B)XHA[:]>^3_`+;6_,+*C>T77M-NXT95MSE')4VOEE))=*DU1RIPKR,M MOO=I%R#C>QIIO]2X4KXG4B]DO,L9YMYG399U[2'=FVVV[]75U\8G&?=;;TXT_;7.E^'"GYFDKLDYED&3J9 MKA(NJ\KR'Z]SN)D2ENB^X[^"KJFY]`_>ZYD_N5K^CJXNOIXWOA5QMR7Z?&O$ M\X]VMN0CT+&N)+[OXG/8^7]R3.EHMKGF)Q(QGU//PXUM,>$57VU9CN,16R-? M';J/9-<7!_VU][9F7&>NZ_@6,5?`L6UZ&&G%)4K3W>/D/IX M/[?,,X.KI+=(+]K?6;;86^36(M^_S``O4&+':;W:KZ]MSQ1H-U5?$R)4\/8# MV*^G;8O8;39K0DLSF+?'V-L7=]AB7'>BRF69,64R['DQGVP=8D1WVR:>8>9-";=9>:-1(2 M14(55%\-;%\5P?,ZR^8CL#ML[=:AKT:S@'A:O95%56X?%V%,A^=4;I$'==_/ M0=3.QC'"/"V%9`.6X7Q#QAB.4I%D0AR7%\$QBBO4A3>A9<5+6KK(LWW>7Z8^ MH'7TF@INB[)H0'/)L6QG-**PQ?,<=I!\DR"PRS(^%.)LARFV<;=M,DO>/<4M[VQ=99".TY- MMI]5(G27&V&Q`5,U5!%$3P30'F_V]\`R6U9D\&<.OM%X$T]QGA;C9(J*BH0% M2J*^"Z$]3#3A'&O'/&<.=7<<8#AN`5]I-2QLH&%XS3XS#L+#TA82;,B4T.&S M)EHP"!ZA"I(*(F^VA!KF'&7&W(A5I<@DH`RCKO MC$*9[@[(1H4<5OI4NA-]]M">IA6+MX[?RFP+)>"^'?B-7*C3JRP3C3#1G5TV M&\$B)+A2PIA?C28K[8FV8$A`0HJ*BIH0+"OBN^Z[[[[[JB[_`%[^>^@$%Y8[ M6>VWG53%=OG`W&\5N M'@'"W%6&QV10&QQW`<8JS04\D)Z+6`^>WY270FK.[F'$?%'(/LY MG4++\>CF9AAV/Y))IH\EQIV0Q5NW%?,.`R\XR!$+2B*J*>'AH0%R;VY]O5DP ML6PX&X9G1E\V)7&.%O-+^<#I5'0GJ?F*;C^/4&)TM;C>+4=3C>/4T4(5114- M=$J:>KAMJ2MQ*^M@M,1(<<")50&P$4557;QT("#D?!'!^8Y%(R[+^&^+,KRN M6U&8E9+DF`XM>7TEF&WZ41I^VLJN3.="*U[+:$:]`^">&@/F>[>N`)#/N\C@ MOAU]A=D5EWC/##:7;RZ@*F42V_+H35^9Y?\`3?V\_AO\)_N(X>_"WXD_%GX: M_=QB/P#\4>X?#/Q%\(^$^X?&_AO^;^\^GZWH>QU=/AH0+,?VB_G%_&NJY6;< MIJXU\:^W+D_>B8MQ_3P--D\M6>*:YHGJ?/A7[D#9/J3^#7AZ<*]7&K]K_B3U MR\S.GIQ]OXO^)'4_LD#7DHQ2HDJ?B>/C7Q!^7]&E%TJ*2Z4Z^\5X4\`:D#-> MYU^QRK,.(^(\?R._I;#++*9992-3<2:Z"U@E:/5;OVS44VB(74ZQ`R(11!5% MWWT`[2CFTZ^\1G'6_58$$$DWW3Z=`$ M#E6BE9;!HL9I^3I7&UZ[>P;:,]5RH@6U["KO4.75,1'9#,B3'=%>HO30AW%$ M)%'=-`*GN@-[F7LMMHKCAJ(HB`/MN.+X"*>&ZKY)^;0'-JKRDO1?*DN:FX&* M[Z$DJNQAV`QGO']D^41YX6C\%\"5%7;0!G]E_>?T=`:G]LOYQ?QKH#70`T`-`#0`T!A5$44C)!`44 MC)?(0%%(B7\@BF^@(\,4JJ;ES/N7>X7D.R]TXEH5F8?2PS=P#ABOB/6B>::`2S"**CY*[FKC-QF'/HN+7K&AI;FRD@ MY.R[/):./VZUY>P#E+A\!U&&&F!%IM!%53C-2^"`^T2.@Q/>9('ME]H21%^K0'.P(H\SNOS:/A4*/6X M1@/&]3AEXW5L!&JG;T9HS(<(FV$!DYM:#IINJ$:"*^/CH#G=Q%2QR/S%POQ$ M,BP=:G37,RS&`$]_X6QBV/FX^T,BL`DBE*LI+9!ZCB$OLB@[:`UP*DAEWB\B MV&$UL2HQ'%L!JZ'*FZ:(U"J964RT9D,1#CQ@:BE8,->)IT]:>EN7GH#3N*B7 M'*7,/$O"N/2O=F:EUWDG+9_0$@*J%"<2+7/FR:$V<@=G%8$MT5UT-_!-`8G\ M8T4;NDXLB836+#_`N*7>49[>`9O64]RX-^)4CD-F2E(GV=H\CA_M54E!5V1` M1-@%LSS-K"QS:JXBQ.P^#VLVD?RK-\G`VT$\01GL=QNSDN*],SKD&6W(D3KDY4MP MY5P]4P0<<%XE,T%!<\!)-`&[O50)F#X_C,1E^VRC.KV)B.*T2N)[D,B0^U(G MW90A3=V=%CMBPVX2J+`O$HBA*JZ`5'C_`+=L'Q/\$7]M7-W?(>(US3*9:\_* M1_WI:\8!QH[`O^[C55[&[45GIZ6P3?[1*N@$([J:.3R;GV"<.8ZX[8Y+D#L6 M\MGI:C(K,$Q2J>)7[)J(*`R,VW>(C<<<57'09!H5025%`3]W#,=RWFZSMJN7 M(IN..WJBEQ\_Y%;?,<@RZ_&#(6Y@K=(76;YQ^J/[!C[M'0@:0.IM-`+;VBXM M7>CGO*359`QZ3R;:1["GQ.O%M@*'"(QR&L:2#&G>Z@B$R5U M.BJIN(@BX;9>:[Z`>G^?ST!Z?V7]Y_1T!J?VR_G%_&N@-=`#0`T`-`#0'FZR MS)9>8?%29?9=9<%%4>H'@)LQZAV4>H"5-_--`(+AO;A@6'-1X`3MLI:O>F2=2)OXZ`7IYM'VG624A1 MUEUE2`N@P%QL@Z@)$]DQ0O979=M`)-Q9PGA7$4)R+C:6MA(=>FO?%,@G_$9[ M*6+Z2)C,-4;98A-27!%7?2`2>Z1ZU+9-`=G+.-JG*KNFR@+*XQS*:&%9U-?D M./O1&K`:>X%L;"O<]_ASXQ-N$VA@?I^HR?B"HN@/MP_"\0XQH':JCCLU5;Z\ MFSM+.?*]698S)'4Y.M;RUE$)S);GBI..*B(G@*(GAH!IG#M"O-7)?+?.#&47 M=&`WKO'^"V./R*Y7TQFGC`U8];-C"L8RMV#A-F!^FA@:*0$F@'?8;@^-X%4G M3XW"*.U(F2+*QF27G9EK;VDPE.79V]C((I,ZPDFJJ9DOT[(B(FV@";:\+8M; MV/(=T=ADM=>\DU-936]U67!1;"IKZCI6''QMX&=ZIOU&T(T3KZU\]`&[#,(I ML'KG(=:=A/FRR8.VL."75&;M(,86WIS(](]3)N>@1(BJ M"^.X'U<7\&X-Q,=D_C@6X)Y)H`^Z`3FHXPQNFR_-<\BG:.93G46-"M+.5/5]R!!AM>C&@T:>D"5D M9I/:1$ZE]1$7==M`%,NWS`@XKN.(8AWD/',@EOSKBP8LD+(+"=*L&K&5,F6# MS!A*=D/,B!H;:BK0].V@%'PO"J#`:6-1X]'=!AAN,#LN8^>*_)RF0UG\NTGS8K]XX4"EL;?K]YM M*.N1CW1NS!'%%M]\7G`!5$51-`*GQWQMC'&%!&Q_&FYCC3$>-'=LK60LVUF- MQ&_2C-2)9".T>*WX-M`(--HJ]([JJJ`?M`>G]E_>?T=`>J^:_P!1YKY^?G]/ MY=`8^[Z`'W?0`^[Z`'W?0`^[Z`'W?0`^[Z`'W?0`^[Z`'W?0";7_N_\-`?_V3\_ ` end